GlassScriptPhysician profile
Edward J Licitra
NPI 1538139548
$29,948.39
in general payments reported to CMS, 2019-2025
32 companies · $973 in 2025
The $973 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $5,597 · 2021: $143 · 2022: $5,080 · 2023: $6,714 · 2024: $268 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,500 · Food and Beverage: $2,479 · Consulting Fee: $2,000 · Travel and Lodging: $930 · Education: $46.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,500.00 |
| Food and Beverage | $2,478.81 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $930.00 |
| Education | $46.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $13,609.95 | 2019-2023 | |
| Daiichi Sankyo INC. | $5,826.99 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,777.14 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $2,020.00 | 2020 | |
| Mirati Therapeutics, INC. | $1,270.11 | 2023-2024 | Krazati |
| Seagen INC. | $750.00 | 2023 | |
| Asd Specialty Healthcare, LLC | $553.49 | 2019-2025 | |
| Avyxa Pharma, LLC | $428.14 | 2025 | |
| Adaptive Biotechnologies Corporation | $363.11 | 2019-2021 | |
| Foundation Medicine, INC. | $300.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $245.35 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Caris Mpi, INC. | $212.00 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $187.64 | 2024 | |
| Karyopharm Therapeutics INC. | $156.29 | 2020-2025 | Xpovio |
| Cardinal Health 110 LLC | $150.00 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $146.91 | 2022-2023 | Xgeva, Kyprolis, Lumakras |
| Exelixis INC. | $128.47 | 2022 | |
| Epizyme, INC. | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.95 | 2019 | |
| Servier Pharmaceuticals LLC | $120.71 | 2023 | |
| Celgene Corporation | $95.00 | 2019 | |
| Blueprint Medicines Corporation | $93.47 | 2023 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $46.20 | 2025 | |
| Astellas Pharma US INC | $38.09 | 2023-2025 | Xtandi |
| Cardinal Health 108 LLC | $37.00 | 2019 | |
| Abbvie INC. | $35.23 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.79 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.90 | 2024 | Libtayo |
| Pfizer INC. | $19.49 | 2025 | |
| Secura Bio, INC. | $17.81 | 2019 | |
| Verastem, INC. | $15.44 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Licitra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.